JP2002511084A - 選択性甲状腺ホルモン類似体 - Google Patents

選択性甲状腺ホルモン類似体

Info

Publication number
JP2002511084A
JP2002511084A JP50453099A JP50453099A JP2002511084A JP 2002511084 A JP2002511084 A JP 2002511084A JP 50453099 A JP50453099 A JP 50453099A JP 50453099 A JP50453099 A JP 50453099A JP 2002511084 A JP2002511084 A JP 2002511084A
Authority
JP
Japan
Prior art keywords
formula
compound
hydrogen
compounds
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50453099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002511084A5 (enExample
Inventor
スキャンラン、トーマス、エス．
シェリニ、グレージア
ヨシハラ、ヒカリ
エイプリレッティ、ジェームズ
バクスター、ジョン、デー．
シー．、ジェー． リベイロ、ラルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2002511084A publication Critical patent/JP2002511084A/ja
Publication of JP2002511084A5 publication Critical patent/JP2002511084A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP50453099A 1997-06-18 1998-06-08 選択性甲状腺ホルモン類似体 Ceased JP2002511084A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/877,792 US5883294A (en) 1997-06-18 1997-06-18 Selective thyroid hormone analogs
US08/877,792 1997-06-18
PCT/US1998/011758 WO1998057919A1 (en) 1997-06-18 1998-06-08 Selective thyroid hormone analogs

Publications (2)

Publication Number Publication Date
JP2002511084A true JP2002511084A (ja) 2002-04-09
JP2002511084A5 JP2002511084A5 (enExample) 2006-01-05

Family

ID=25370738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50453099A Ceased JP2002511084A (ja) 1997-06-18 1998-06-08 選択性甲状腺ホルモン類似体

Country Status (9)

Country Link
US (1) US5883294A (enExample)
EP (1) EP0991618B1 (enExample)
JP (1) JP2002511084A (enExample)
KR (1) KR20010013999A (enExample)
AT (1) ATE254095T1 (enExample)
AU (1) AU746991B2 (enExample)
CA (1) CA2290622C (enExample)
DE (1) DE69819726T2 (enExample)
WO (1) WO1998057919A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
JP2008545711A (ja) * 2005-05-26 2008-12-18 メタバシス・セラピューティクス・インコーポレイテッド 新規ホスフィン酸含有甲状腺ホルモン様剤
JP2009531359A (ja) * 2006-03-28 2009-09-03 カロ バイオ アクチェブラーグ 甲状腺ホルモン受容体アゴニストを含有する安定な経口医薬組成物
JP2023530708A (ja) * 2020-06-17 2023-07-19 オートバーン セラピューティクス，インク． 甲状腺様作用剤

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0873361B1 (en) 1995-12-13 2006-11-02 The Regents Of The University Of California Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6217598B1 (en) * 1997-11-25 2001-04-17 Linvatec Corporation End-cutting shaver blade
EP1598334A1 (en) * 1998-06-30 2005-11-23 The Regents Of The University Of California Thyroid hormone analogues and methods for their preparation
AR018699A1 (es) 1999-06-01 2001-11-28 Procter & Gamble Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afecta al corazon
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
CA2374263A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylether derivatives
WO2000072813A1 (en) * 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6516294B1 (en) 1999-07-01 2003-02-04 The Regents Of The University Of California Nuclear receptor for 1α,25-dihydroxyvitamin D3 useful for selection of vitamin D3 ligands and a method therefor
DE10024939A1 (de) 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
US6716877B2 (en) 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US6534676B2 (en) 2001-01-31 2003-03-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
US7504435B2 (en) 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US20040253648A1 (en) * 2002-12-10 2004-12-16 The Regents Of The University Of California Method for creating nuclear receptor activity modulating pharmaceuticals
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
WO2005085865A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
US20060292194A1 (en) * 2005-06-24 2006-12-28 Thomas Lavin Treatment for burns and adipose deposits using thyroid hormone compound in a human
KR100965006B1 (ko) 2005-07-21 2010-06-21 에프. 호프만-라 로슈 아게 갑상선 호르몬 수용체 작용제로서 피리다진온 유도체
AU2008219585A1 (en) * 2007-02-27 2008-09-04 The Arizona Board Of Regents On Behalf Of The University Of Arizona Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
JP2016517883A (ja) 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP2018510849A (ja) * 2015-02-20 2018-04-19 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ ソベチロムの誘導体
US11872207B2 (en) 2015-12-24 2024-01-16 Mcmaster University Dronedarone and derivatives thereof for treating cancer
CA3008041C (en) 2015-12-24 2024-02-13 Mcmaster University Compounds for treating cancer
KR102331596B1 (ko) 2016-05-18 2021-11-25 오레곤 헬스 앤드 사이언스 유니버시티 소베티롬의 유도체
US11325886B2 (en) 2016-08-12 2022-05-10 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11660281B2 (en) * 2017-06-29 2023-05-30 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
WO2019160980A1 (en) 2018-02-14 2019-08-22 Oregon Health & Science University Derivatives of sobetirome
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CA3122996A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
IT201900006923A1 (it) * 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
KR20220121239A (ko) 2019-11-29 2022-08-31 아우토반 쎄라퓨틱스, 인크. 신규한 갑상선 호르몬 모방제
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
US20230242473A1 (en) * 2020-06-17 2023-08-03 Autobahn Therapeutics, Inc. Thyromimetics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56115746A (en) * 1979-10-09 1981-09-11 Abbott Lab Hydroxyaminomethyl derivatives of benzoylldiisubstituteddalphaaphenoxyalkanoyl esters
JPH05170690A (ja) * 1991-12-20 1993-07-09 Mitsui Toatsu Chem Inc ジフェニル炭化水素誘導体を有効成分として含有する血栓溶解促進剤
JP2002519340A (ja) * 1998-06-30 2002-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 甲状腺ホルモン類似体およびそれらの調製方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323691A (en) * 1979-10-09 1982-04-06 Abbott Laboratories Hydroxyaminomethyl derivatives of benzoyl di-substituted α-phenoxyalkanoyl esters
IT1218855B (it) * 1984-12-28 1990-04-24 Ates Componenti Elettron Stadio amplificatore di segnali, integrato monoliticamente, ad alta dinamica di uscita
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
DE4327365A1 (de) * 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56115746A (en) * 1979-10-09 1981-09-11 Abbott Lab Hydroxyaminomethyl derivatives of benzoylldiisubstituteddalphaaphenoxyalkanoyl esters
JPH05170690A (ja) * 1991-12-20 1993-07-09 Mitsui Toatsu Chem Inc ジフェニル炭化水素誘導体を有効成分として含有する血栓溶解促進剤
JP2002519340A (ja) * 1998-06-30 2002-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 甲状腺ホルモン類似体およびそれらの調製方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
JP2008545711A (ja) * 2005-05-26 2008-12-18 メタバシス・セラピューティクス・インコーポレイテッド 新規ホスフィン酸含有甲状腺ホルモン様剤
JP2009531359A (ja) * 2006-03-28 2009-09-03 カロ バイオ アクチェブラーグ 甲状腺ホルモン受容体アゴニストを含有する安定な経口医薬組成物
JP2023530708A (ja) * 2020-06-17 2023-07-19 オートバーン セラピューティクス，インク． 甲状腺様作用剤

Also Published As

Publication number Publication date
KR20010013999A (ko) 2001-02-26
DE69819726T2 (de) 2004-09-30
EP0991618A1 (en) 2000-04-12
CA2290622C (en) 2008-08-05
CA2290622A1 (en) 1998-12-23
WO1998057919A1 (en) 1998-12-23
EP0991618A4 (en) 2000-09-27
AU7823498A (en) 1999-01-04
US5883294A (en) 1999-03-16
ATE254095T1 (de) 2003-11-15
DE69819726D1 (de) 2003-12-18
AU746991B2 (en) 2002-05-09
EP0991618B1 (en) 2003-11-12

Similar Documents

Publication Publication Date Title
JP2002511084A (ja) 選択性甲状腺ホルモン類似体
JP6101675B2 (ja) 代謝病の治療用の化合物
US6306854B1 (en) Chemical compounds
TWI331992B (en) Lipoxin a4 analogs
JP2002519340A (ja) 甲状腺ホルモン類似体およびそれらの調製方法
EP0703897B1 (en) Lipoxin compounds with prolonged half-life
JPH07103070B2 (ja) 甲状腺ホルモンと類似した作用をする新規化合物
JP4594099B2 (ja) ビタミンｄレセプターモジュレーター
US6326397B1 (en) Retinoid antagonists and use thereof
JP3341019B2 (ja) 選択的ロイコトリエンｂ▲４▼拮抗剤活性を示す置換された単環式アリール化合物
US6274608B1 (en) Compounds, their preparation and use
JP2001501202A (ja) ロイコトリエンｂ４（ｌｔｂ―４）レセプターアンタゴニスト活性によるアリル置換アクリルアミド
JP2796876B2 (ja) 置換ピロリジン化合物および医薬組成物
US7019034B2 (en) Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
JP2002544227A (ja) 新規ジフェニルエチレン化合物
JPH10505348A (ja) 耐性腫瘍の同定および治療方法
JPH0597839A (ja) ホスホリパーゼａ２阻害剤としてのテトロン酸誘導体およびチオテトロン酸誘導体
JPH0379336B2 (enExample)
JPH02270861A (ja) ピロリルフェニル置換ヒドロキサム酸誘導体
AU2589900A (en) Synthesis of dihydrohonokiol compositions
JP2008524259A (ja) ビタミンｄ受容体モジュレーター
WO2003004484A1 (en) Novel aliphatic compounds, synthesis method and method of using the same
JPS62209070A (ja) ネオリグナン誘導体
EP0518769B1 (fr) Nouveaux dérivés de benzoate d'éthanolamine, leur procédé de préparation et les compositions pharmaceutiques les renfermant
JPS6242947A (ja) 新規安息香酸誘導体、これを含有する医薬及びこの化合物を製造する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050608

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100329

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100803

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20101221